Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for baloxavir marboxil

  1. Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal) (TA1135)

    NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating and preventing influenza in children 1 to 11 years. This is because the company did not provide an evidence submission.

    Sections for TA1135

  2. Baloxavir marboxil for treating acute uncomplicated influenza in people 12 years and over (terminated appraisal) (TA732)

    NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating acute uncomplicated influenza in people aged 12 and over. This is because Roche did not provide an evidence submission.

    Sections for TA732

  3. Baloxavir marboxil granules for treating and preventing influenza in people 3 weeks and over [TSID12432]

    Awaiting development Reference number: GID-TA12479 Expected publication date: TBC

  4. Baloxavir marboxil for treating influenza in people 12 years and over at high risk of complications [ID3794]

    Awaiting development Reference number: GID-TA10683 Expected publication date: TBC

  5. Baloxavir marboxil for preventing influenza in people 12 years and over [ID3793]

    In development Reference number: GID-TA10684 Expected publication date: TBC

  6. Baloxavir marboxil for treating and preventing influenza in babies 3 weeks to under 1 year [ID6555]

    Discontinued Reference number: GID-TA11712

  7. Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]

    In development Reference number: GID-TA11646 Expected publication date: TBC